

**ASX Announcement | 6 October 2020  
Visioneering Technologies (ASX:VTI)**

**Visioneering Technologies, Inc. to Present at the SNN Network  
Australia Virtual Event on Wednesday 11 November 2020 8:30 am  
Sydney Time (Tuesday 10 November at 4:30 pm New York Time)**

**Atlanta, GA, USA 6 November 2020:** Visioneering Technologies (ASX:VTI), US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses Visioneering Technologies, Inc. is pleased to announce that it will be participating in the SNN Network Australia Virtual Event.

The company presentation will be held on Wednesday 11 November 2020 at 8:30 am Sydney Time. Chief Executive Officer Dr. Stephen Snowdy, PhD, will be hosting the presentation and answering questions from investors.

Dr. Snowdy will also participate in a panel titled, “Learn About the ASX: Technology, Operations in the US”, hosted by well-known Australian MicroCap analyst, investor and founder of Coffee Microcaps, Mark Tobin. The panel session will be held on Tuesday 10 November 2020 at 9:00 am Sydney time. The panel session will be archived on the conference website following the webcast.

The URL for the company presentation is <https://www.webcaster4.com/Webcast/Page/2059/38576>.  
The URL for the panel is <https://www.webcaster4.com/Webcast/Page/2059/38583>.

For information and registration for the event, please visit <https://australia.snn.network/signup>.

**Ends**

**This release was authorized by the CEO, Stephen Snowdy, PhD.**

**For more information, please contact:**

**Visioneering Technologies**

**Stephen Snowdy**

CEO

E: [ssnowdy@vtivision.com](mailto:ssnowdy@vtivision.com)

**Investor & Media Relations**

**Julia Maguire**

The Capital Network

M: +61 02 8999 3699

E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

**About Visioneering Technologies**

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Visioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and VTI has expanded its portfolio of

technologies to address a range of eye care issues. The company has grown operations across the United States, Canada, Australia, and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

### Foreign ownership restrictions

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX40